Michele Cimminiello

Potenza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 09, 2026

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

Journal: EClinicalMedicine
Published: April 09, 2026

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 22, 2026

Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.

Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 26, 2025

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Journal: HemaSphere
Published: September 08, 2025

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology
Published: August 22, 2025

CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy.

CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy.

Journal: Cancers
Published: July 19, 2025

Multiple myeloma patients treated with lenalidomide-based regimens frequently experience delayed peripheral blood stem cell collection: A controlled real-life study.

Multiple myeloma patients treated with lenalidomide-based regimens frequently experience delayed peripheral blood stem cell collection: A controlled real-life study.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Published: July 13, 2025

Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.

Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.

Journal: Frontiers in oncology
Published: May 12, 2025

Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study.

Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study.

Journal: American journal of hematology
Published: March 17, 2025

Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey).

Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey).

Journal: Leukemia & lymphoma
Published: January 15, 2025

Perception of 'patient safety culture' among healthcare professionals in the field of haematopoietic stem cell transplantation and CAR-T therapy: a multicentre cross-sectional observational study by Italian Transplant Group for Bone Marrow Transplantation, Haematopoietic Stem Cells and Cell Therapy (GITMO).

Perception of 'patient safety culture' among healthcare professionals in the field of haematopoietic stem cell transplantation and CAR-T therapy: a multicentre cross-sectional observational study by Italian Transplant Group for Bone Marrow Transplantation, Haematopoietic Stem Cells and Cell Therapy (GITMO).

Journal: BMJ open quality
Published: January 10, 2025
Showing 1-12 of 36

Last Updated: 09/26/2026